Opzelura is a medicine used for treating non-segmental vitiligo, a disease that causes patches of skin to lose colour on both sides of the body. In patients with vitiligo, the immune system (the body’s natural defences) attacks melanocytes (the skin cells that make pigment), causing patches of pale pink or white skin (depigmentation). Opzelura is used in adults and adolescents from 12 years of age with non-segmental vitiligo that also affects the face. Opzelura contains the active substance ruxolitinib.
Therapeutic Indication
### Therapeutic indication Opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
Therapeutic Area (MeSH)
ATC Code
D11AH
ATC Item
皮炎治疗药, 不包括皮质类固醇
Pharmacotherapeutic Group
Other dermatological preparations
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| ruxolitinib phosphate | N/A | 磷酸芦可替尼 |
EMA Name
Opzelura
Medicine Name
Opzelura
Aliases
N/A
